

[AMP case report: A case of a rare myeloid neoplasm presenting with features mimicking primary myelofibrosis](#)

written by CAP TODAY
February 18, 2022

February 2022—Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders characterized by increased proliferation of myeloid cells of one or more lineage. The most common MPNs include chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). CML is defined by the *BCR-ABL1* fusion, which typically results from the t(9;22)(q34;q11.2) rearrangement.



©2026 CAP TODAY, all rights reserved.

[The rush to deliver integrated reporting in pathology](#)

written by CAP TODAY
February 18, 2022

February 2022—Oracle’s purchase of Cerner, cloud computing, and integrated reporting were up for discussion when CAP TODAY publisher Bob McGonnagle convened a virtual roundtable Jan. 6 on anatomic pathology computer systems. Hematopathologist Monica E. de Baca, MD, said on the call she was encouraged by what she heard about integrated reporting from the AP LIS vendor reps on the call. But she said: “We should also be thinking about what is next; we don’t want to be talking about things 10 years after they were needed.” She and seven others answered McGonnagle’s questions, among them: Are the resources in pathology adequate to make progress toward and enable the necessary IT outcomes?

[From the President's Desk](#)

written by CAP TODAY
February 18, 2022

The time for courage

February 2022—We pathologists tend to share traits common among physicians: We are often type A overachievers, driven by perfectionism, our own unrealistic expectations, and a deep fear of failure. Normally, these characteristics help us to achieve our goals, in life and in caring for patients. But these are not normal times. In the COVID-19 pandemic, it is almost impossible to feel like we're doing a good job. Like so many of you, I am working significantly longer hours than usual. At the end of each day I am often left with a sense of despondency that there's not enough time to get everything done, or to do it all as well as I would like. To get through this crisis, we have to let go of our perfectionism and embrace doing what we can. We need to accept that if we're doing what we can, it's enough. Even if our individual efforts seem inadequate in dealing with this pandemic nightmare, the collective effort is adequate. Each day in my hospital I feel like I'm taking a bath in COVID-19. But I go home, rest up, and do it again the next day.

[Clinical pathology selected abstracts](#)

written by CAP TODAY
February 18, 2022

- Association of preanalytical error with use of outdoor courier lockboxes in summer

- Enhancing diversity, equity, and inclusion in pathology training programs



©2026 CAP TODAY, all rights reserved.

[Anatomic pathology selected abstracts](#)

written by CAP TODAY
February 18, 2022

- Use of subtyping to predict behavior of papillary thyroid microcarcinomas
- Gastrointestinal pathology in samples from COVID-19-positive patients
- Assessment of an artificial intelligence system for prostate cancer detection
- Expression patterns for Bcl-2, EMA, β -catenin, E-cadherin, PAX8, and MIB-1 in thymomas
- Analysis of intraoperative frozen section biopsy of uterine smooth muscle tumors



©2026 CAP TODAY, all rights reserved.

[Molecular pathology selected abstracts](#)

written by CAP TODAY
February 18, 2022

- Use of a 21-gene assay to inform chemotherapy benefit in node-positive breast cancer
- Benefits of gene therapy to treat beta-thalassemia

Q&A column

written by CAP TODAY
February 18, 2022

February 2022

Q. Are there established benchmarks for such transfusion services quality monitors as C:T ratio, blood product waste, and cancellation of suboptimal specimens? [Read answer.](#)

Q. If we collect only enough blood to inoculate one blood culture bottle, should we inoculate the aerobic or anaerobic bottle? [Read answer.](#)

Newsbytes

written by CAP TODAY
February 18, 2022

February 2022—Ask TRUU-Lab founder Ila Singh, MD, PhD, what’s in a name and she will provide an answer that differs greatly from that of Shakespeare’s Juliet Capulet. According to Dr. Singh, the answer can be too much information, not enough information, or ambiguous terminology—when referring to lab test names, that is.

Put It on the Board

written by CAP TODAY
February 18, 2022

February 2022—Siemens Healthineers' Enhanced Liver Fibrosis test is available in the United States, exclusively through collaboration with Labcorp and Quest Diagnostics. This commercial availability in the U.S. follows de novo marketing authorization from the FDA in August 2021.

Letters

written by CAP TODAY
February 18, 2022

February 2022—The CDC published on Nov. 5, 2021 a report indicating that immunocompromised persons receiving SARS-CoV-2 mRNA vaccines should receive three doses and a booster (*MMWR Morb Mortal Wkly Rep.* 2021;70[44]:1553-1559). The following n-of-1 observational study suggests that an immunocompromised nonresponder to mRNA vaccine may indeed respond to a second series of SARS-CoV-2 mRNA vaccine.

